Targeting ornithine decarboxylase by α-difluoromethylornithine inhibits tumor growth by impairing myeloid-derived suppressor cells

Journal of Immunology

Volumn 196, Issue 2, 2016, Pages 915-923

  Ye, Cong ^a,b,c   Geng, Zhe ^b,d   Dominguez, Donye ^b   Chen, Siqi ^b   Fan, Jie ^b   Qin, Lei ^b   Long, Alan ^b   Zhang, Yi ^a   Kuzel, Timothy M ^b   Zhang, Bin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Hubei Maternal and Child Health Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ARGINASE; CD39 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFLORNITHINE; GAMMA INTERFERON; ORNITHINE DECARBOXYLASE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; ORNITHINE DECARBOXYLASE INHIBITOR;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTIC INFILTRATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; BONE MARROW CELL; C57BL MOUSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOLOGY; KNOCKOUT MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ESCAPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; EFLORNITHINE; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; ORNITHINE DECARBOXYLASE; ORNITHINE DECARBOXYLASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR ESCAPE;

EID: 84954130255     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500729     Document Type: Article

References (41)

1. Gajewski, T. F. 2006. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 12: 2326s-2330s.
2. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
3. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosup-pressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
4. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
5. Filipazzi, P., V. Huber, and L. Rivoltini. 2012. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61: 255-263.
6. Ostrand-Rosenberg, S. 2010. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59: 1593-1600.
7. Arina, A., and V. Bronte. 2015. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 33: 120-125.
8. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
9. Kirkwood, J. M., A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. Butterfield, and H. J. Gogas. 2008. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26: 3445-3455.
10. Postow, M. A., J. Harding, and J. D. Wolchok. 2012. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 18: 153-159.
11. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, and V. Bronte. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22: 238-244.
12. Youn, J. I., and D. I. Gabrilovich. 2010. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40: 2969-2975.
13. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553.
14. Schlecker, E., A. Stojanovic, C. Eisen, C. Quack, C. S. Falk, V. Umansky, and A. Cerwenka. 2012. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189: 5602-5611.
15. Umansky, V., and A. Sevko. 2012. Melanoma-induced immunosuppression and its neutralization. Semin. Cancer Biol. 22: 319-326.
16. Kehe, C. R., and J. W. Harris. 1978. Ornithine decarboxylase and polyamines in the resumption of cycling by diluted and reoxygenated mammalian cells. Exp. Cell Res. 115: 405-408.
17. Milord, F., J. Pépin, L. Loko, L. Ethier, and B. Mpia. 1992. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340: 652-655.
18. Casero, R. A., Jr., and L. J. Marton. 2007. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 6: 373-390.
19. Gerner, E. W., and F. L. Meyskens, Jr. 2004. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4: 781-792.
20. Meyskens, F. L., Jr., and E. W. Gerner. 1999. Development of difluoro-methylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 5: 945-951.
21. Babbar, N., and E. W. Gerner. 2011. Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res. 188: 49-64.
22. Wang, L., J. Fan, L. F. Thompson, Y. Zhang, T. Shin, T. J. Curiel, and B. Zhang. 2011. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121: 2371-2382.
23. Jin, D., J. Fan, L. Wang, L. F. Thompson, A. Liu, B. J. Daniel, T. Shin, T. J. Curiel, and B. Zhang. 2010. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70: 2245-2255.
24. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
25. Chen, S., L. Wang, J. Fan, C. Ye, D. Dominguez, Y. Zhang, T. J. Curiel, D. Fang, T. M. Kuzel, and B. Zhang. 2015. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 75: 519-531.
26. Borsellino, G., M. Kleinewietfeld, D. Di Mitri, A. Sternjak, A. Diamantini, R. Giometto, S. Höpner, D. Centonze, G. Bernardi, M. L. Dell'Acqua, et al. 2007. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232.
27. Ryzhov, S., S. V. Novitskiy, A. E. Goldstein, A. Biktasova, M. R. Blackburn, I. Biaggioni, M. M. Dikov, and I. Feoktistov. 2011. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J. Immunol. 187: 6120-6129.
28. Ngo, T. T., K. L. Brillhart, R. H. Davis, R. C. Wong, J. H. Bovaird, J. J. Digangi, J. L. Ristow, J. L. Marsh, A. P. Phan, and H. M. Lenhoff. 1987. Spectrophoto-metric assay for ornithine decarboxylase. Anal. Biochem. 160: 290-293.
29. Ma, Q., Y. Wang, X. Gao, Z. Ma, and Z. Song. 2007. L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin. Cancer Res. 13: 7407-7412.
30. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell sub-populations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
31. Huang, B., P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S. H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131.
32. Tomihara, K., M. Guo, T. Shin, X. Sun, S. M. Ludwig, M. J. Brumlik, B. Zhang, T. J. Curiel, and T. Shin. 2010. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J. Immunol. 184: 6151-6160.
33. Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
34. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580.
35. Bowlin, T. L., B. J. Hoeper, A. L. Rosenberger, G. F. Davis, and P. S. Sunkara. 1990. Effects of three irreversible inhibitors of ornithine decarboxylase on macrophage-mediated tumoricidal activity and antitumor activity in B16F1 tumor-bearing mice. Cancer Res. 50: 4510-4514.
36. Bowlin, T. L., B. J. McKown, G. F. Davis, and P. S. Sunkara. 1986. Effect of polyamine depletion in vivo by DL-alpha-difluoromethylornithine on functionally distinct populations of tumoricidal effector cells in normal and tumor-bearing mice. Cancer Res. 46: 5494-5498.
37. Hayes, C. S., A. C. Shicora, M. P. Keough, A. E. Snook, M. R. Burns, and S. K. Gilmour. 2014. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol. Res. 2: 274-285.
38. Raber, P., A. C. Ochoa, and P. C. Rodŕiguez. 2012. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol. Invest. 41: 614-634.
39. Reczkowski, R. S., and D. E. Ash. 1994. Rat liver arginase: kinetic mechanism, alternate substrates, and inhibitors. Arch. Biochem. Biophys. 312: 31-37.
40. Selamnia, M., C. Mayeur, V. Robert, and F. Blachier. 1998. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem. Pharmacol. 55: 1241-1245.
41. Iannone, R., L. Miele, P. Maiolino, A. Pinto, and S. Morello. 2013. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15: 1400-1409.